-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Branebrutinib in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Branebrutinib in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Branebrutinib in Rheumatoid Arthritis Drug Details: Branebrutinib (BMS-986195) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REC-4881 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REC-4881 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REC-4881 in Solid Tumor Drug Details: REC-4881 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REC-4881 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REC-4881 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REC-4881 in Colorectal Cancer Drug Details: REC-4881 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LGK-974 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LGK-974 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LGK-974 in Triple-Negative Breast Cancer (TNBC) Drug Details: LGK-974 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – REC-4881 in Familial Adenomatous Polyposis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REC-4881 in Familial Adenomatous Polyposis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REC-4881 in Familial Adenomatous Polyposis Drug Details: REC-4881 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lemzoparlimab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lemzoparlimab in Marginal Zone B-cell Lymphoma Drug Details: TJC-4...
-
Product Insights
Fragile X Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Fragile X Syndrome - Drugs In Development, 2023’, provides an overview of the Fragile X Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Charcot-Marie-Tooth Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Charcot-Marie-Tooth Disease - Drugs In Development, 2023’, provides an overview of the Charcot-Marie-Tooth Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...